Coherus BioSciences is a biopharmaceutical company that focuses on the biosimilar and immuno-oncology market. It markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor. The company also develops toripalimab, an anti-PD-1 antibody for the treatment of melanoma, urothelial cancer, and nasopharyngeal carcinoma; bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions.